| 2022 | 2LBA Late Breaking - Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC) | EUROPEAN JOURNAL OF CANCER |
| 2005 | A Carcinoembryonic Antigen-Secreting Adenocarcinoma Arising in Tailgut Cyst : Clinical Implications of Carcinoembryonic Antigen
| YONSEI MEDICAL JOURNAL |
| 2016 | A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib | JOURNAL OF THORACIC ONCOLOGY |
| 2004 | A case of lactic acidosis caused by stavudine in an AIDS patient
| KOREAN JOURNAL OF INTERNAL MEDICINE |
| 2012 | A case of synchronous squamous cell carcinoma in the esophagus and stomach
| GUT AND LIVER |
| 2018 | A Clinical Trial of Combination Neoadjuvant Chemotherapy and Transoral Robotic Surgery in Patients with T3 and T4 Laryngo-Hypopharyngeal Cancer | ANNALS OF SURGICAL ONCOLOGY |
| 2016 | A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806) | LUNG CANCER |
| 2022 | A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11) | CLINICAL LUNG CANCER |
| 2013 | A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes | ANNALS OF ONCOLOGY |
| 2022 | A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors
| JOURNAL OF THORACIC ONCOLOGY |
| 2022 | A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer | EXPERT OPINION ON INVESTIGATIONAL DRUGS |
| 2013 | A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC) | LUNG CANCER |
| 2019 | A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs | Lung Cancer |
| 2023 | A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma
| ESMO OPEN |
| 2023 | A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer
| ESMO OPEN |
| 2023 | A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study)
| CANCERS |
| 2021 | A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
| CANCER MEDICINE |
| 2020 | A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy | ANNALS OF ONCOLOGY |
| 2005 | A Pilot Study of Trans-Arterial Injection of 166Holmium-Chitosan Complex for Treatment of Small Hepatocellular Carcinoma
| YONSEI MEDICAL JOURNAL |
| 2023 | A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamab
| FUTURE ONCOLOGY |
| 2014 | A prospective phase II trial of s-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2022 | A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial | ANNALS OF ONCOLOGY |
| 2023 | A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non-small cell lung cancer with EGFR mutation
| CANCER |
| 2016 | A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2017 | A randomized; phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) (vol 8; pg 15943; 2017)
| ONCOTARGET |
| 2023 | A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data | FUTURE ONCOLOGY |
| 2008 | A single institutional experience of surgically resected thymic epithelial tumors over 10 years: clinical outcomes and clinicopathologic features | ONCOLOGY REPORTS |
| 2014 | A Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer | JOURNAL OF MOLECULAR DIAGNOSTICS |
| 2015 | Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M | NATURE MEDICINE |
| 2010 | Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells. | CANCER LETTERS |
| 2018 | Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies | CNACER TREATMENT REVIEWS |
| 2009 | Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma. | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY |
| 2012 | Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation | MOLECULAR CANCER THERAPEUTICS |
| 2016 | Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy
| ONCOGENESIS |
| 2017 | Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study | LANCET RESPIRATORY MEDICINE |
| 2023 | Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2018 | Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea | LUNG CANCER |
| 2016 | Alteration status and prognostic value of MET in head and neck squamous cell carcinoma
| JOURNAL OF CANCER |
| 2023 | Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer EGFR Exon 20 insertion mutations after platinum-based chemotherapy
| ACTA ONCOLOGICA |
| 2021 | Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study | JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions | NEW ENGLAND JOURNAL OF MEDICINE |
| 2023 | Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial
| NATURE MEDICINE |
| 2023 | Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications
| CLINICAL LUNG CANCER |
| 2015 | An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer | EUROPEAN JOURNAL OF CANCER |
| 2021 | Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study
| CANCERS |
| 2024 | Analysis of tumor mutational burden and mutational landscape comparing whole-exome sequencing and comprehensive genomic profiling in patients with resectable early-stage non-small-cell lung cancer
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2021 | Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer | LUNG CANCER |
| 2023 | Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial
| JAMA ONCOLOGY |
| 2022 | Antibody-Drug Conjugates: A New Addition to the Treatment Landscape of EGFR-Mutant Non-Small Cell Lung Cancer | CANCER RESEARCH |
| 2022 | Anticancer effect of verteporfin on non-small cell lung cancer via downregulation of ANO1
| BIOMEDICINE & PHARMACOTHERAPY |
| 2015 | Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma
| MOLECULAR CANCER THERAPEUTICS |
| 2020 | Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC | CANCER DISCOVERY |
| 2011 | Apoptosis and growth inhibition by sprouty2 in non-small cell lung cancer | Dissertation |
| 2017 | Architectural patterns of p16 immunohistochemical expression associated with cancer immunity and prognosis of head and neck squamous cell carcinoma | APMIS |
| 2023 | Artificial intelligence-based non-small cell lung cancer transcriptome RNA-sequence analysis technology selection guide
| FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY |
| 2017 | ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC) | JOURNAL OF THORACIC ONCOLOGY |
| 2023 | Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC
| ANNALS OF ONCOLOGY |
| 2010 | Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial | LUNG CANCER |
| 2023 | Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial
| JOURNAL OF THORACIC ONCOLOGY |
| 2020 | Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
